Department of Biological Sciences, University of Botswana, Private Bag 0022, Gaborone, Botswana.
J Ethnopharmacol. 2012 May 7;141(1):48-56. doi: 10.1016/j.jep.2012.01.044. Epub 2012 Feb 2.
Despite advances in anti-retroviral therapy which has transformed HIV/AIDS from a fatal to a manageable chronic disease, increasing viral drug resistance, side effects and uneven access to anti-retroviral drugs remain considerable therapeutic challenges. Partly as a consequence of these shortcomings and partly based on the fact that HIV/AIDS gives rise to opportunistic infections whose symptoms have been managed in Africa in an HIV/AIDS-independent context by traditional healers for centuries, many HIV/AIDS patients use herbal medicines. The aim of this study was to screen selected medicinal plants from Botswana, used by traditional healers to treat/manage HIV/AIDS, for inhibitory activities on HIV replication.
Based on an ethnomedical survey, ethanolic tannin-containing and tannin-free extracts from 10 medicinal plants were tested for inhibitory properties against a clone of HIV-1c (MJ(4)) measuring cytopathic effect protection and levels of viral p24 antigen in infected PBMCs.
Cassia sieberiana D.C., Cassia abbreviata Oliv. Oliv. and Plumbago zeylanica L. extracts showed significant inhibition of HIV-1c (MJ(4)) replication. The inhibitory activity of the Plumbago zeylanica extract could be attributed to its tannin content. Anti-HIV activity of Cassia sieberiana root and bark extracts, and Cassia abbreviata root extracts occurred in a concentration-dependent manner with an effective concentration (EC(50)) of 65.1μg/ml, 85.3μg/ml and 102.8μg/ml, respectively. Experiments to elucidate possible mechanism(s) of action revealed that Cassia sieberiana root and bark extracts blocked HIV replication at its binding- (EC(50)=70.2μg/ml and 90.8μg/ml, respectively) and entry stage (EC(50)=88.9μg/ml and 100.5μg/ml, respectively) while Cassia abbreviata extracts did not.
We report here for the first time a direct inhibitory effect on HIV-1c replication of extracts from two extremely popular medicinal plants, Cassia sieberiana and Cassia abbreviata. Considering the traditional uses of both Cassia species, our findings strongly suggest pilot clinical observational studies involving traditional healers to further evaluate the therapeutic potential of the Cassia extracts.
尽管抗逆转录病毒疗法取得了进展,将 HIV/AIDS 从致命疾病转变为可管理的慢性疾病,但病毒耐药性增加、副作用和获得抗逆转录病毒药物的不平等仍然是相当大的治疗挑战。部分由于这些缺点,部分由于 HIV/AIDS 引起的机会性感染,这些症状在非洲已经由传统治疗师在 HIV/AIDS 独立的背景下管理了几个世纪,许多 HIV/AIDS 患者使用草药。本研究的目的是筛选博茨瓦纳的传统治疗师用于治疗/管理 HIV/AIDS 的选定药用植物,以检测其对 HIV 复制的抑制活性。
基于民族医学调查,用含和不含单宁的乙醇提取物对 10 种药用植物进行了抑制 HIV-1c(MJ(4))复制的特性测试,通过细胞病变效应保护和感染 PBMC 中病毒 p24 抗原的水平来测量。
决明子 D.C.、短叶决明 Oliv. Oliv. 和白花丹 L. 提取物对 HIV-1c(MJ(4))复制具有显著抑制作用。白花丹提取物的抗 HIV 活性可归因于其单宁含量。决明子根和树皮提取物以及短叶决明根提取物的抗 HIV 活性呈浓度依赖性,有效浓度(EC(50))分别为 65.1μg/ml、85.3μg/ml 和 102.8μg/ml。阐明可能的作用机制的实验表明,决明子根和树皮提取物在结合阶段(EC(50)分别为 70.2μg/ml 和 90.8μg/ml)和进入阶段(EC(50)分别为 88.9μg/ml 和 100.5μg/ml)阻断 HIV 复制,而短叶决明提取物则没有。
我们首次报道了两种非常受欢迎的药用植物决明子和短叶决明提取物对 HIV-1c 复制的直接抑制作用。考虑到这两种决明子的传统用途,我们的发现强烈表明需要进行涉及传统治疗师的试点临床观察研究,以进一步评估决明子提取物的治疗潜力。